Week of August 27, 2012: AstraZeneca Names Pascal Soriot CEO; The Merck Group Agrees to Acquire Biochrom; and More - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of August 27, 2012: AstraZeneca Names Pascal Soriot CEO; The Merck Group Agrees to Acquire Biochrom; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

AstraZeneca has appointed Pascal Soriot as CEO and executive director of the company’s board of directors, effective Oct. 1, 2012. Simon Lowth will remain as AstraZeneca’s interim CEO until Soriot joins. At that point, Lowth will resume his responsibilities as chief financial officer and will continue to serve as an executive director on the board. Read More

Eli Lilly announced that the US Court of Appeals for the Federal Circuit has affirmed a prior ruling by the US District Court for the District of Delaware that the company’s compound patent for Alimta (pemetrexed) is valid. The compound patent provides protection for Alimta in the US through January 2017. Read More

The Merck Group has agreed to acquire Biochrom, a German company that specializes in the production and marketing of cell-culture media and buffer solutions. The acquisition is expected to close in the fourth quarter of 2012, and is subject to customary closing conditions and regulatory approval. Read More

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here